Sanofi and Translate Bio mRNA COVID-19 vaccine candidate induced high antibody
Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio , a clinical-stage messenger RNA (mRNA) therapeutics company, today announced the preclinical results for MRT5500, a mRNA-based vaccine candidate against SARS-CoV-2, the virus that causes COVID-19 disease.
Preclinical evaluation of MRT5500, importantly, demonstrated a favorable immune response profile against SARS-CoV-2. These data support the selection of MRT5500 for clinical development. A Phase 1/2 clinical trial is anticipated to begin in the fourth quarter of 2020. Full results are available here. MRT5500 is being developed under a collaboration agreement between Sanofi Pasteur and Translate Bio.
Looking for chemical products? Let suppliers reach out to you!
CPhI Worldwide to return in 2021
You May Interested In
β-Nicotinamide Adenine Dinucleotide High Quality NAD+ CAS 53-84-9 Exclusive Production Factory CAS NO.53-84-9
$75/UNIT FOB
Chemical Weight LossTirzepatide LY3298176 CAS 2023788-19-2 Vial 10mg 20mg Reta Peptide
$120/UNIT FOB
2026-06-23
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Which Protein Is Present In Covid 19
-
Which Is The Best Covid Vaccine In The World
-
Interpretation Of Omicron Covid Variant Symptoms
-
A Look At The Worst Hit Covid Countries
-
Nitric Oxide Nasal Spray Prevents Spread of Coronavirus, Clinical Trials Show
-
'Delta MayJust Be A Warning', New Variant Of COVID-19 May Emerge
-
What Other Vaccines Use mRNA And The Application Of Homogeneous Technology In mRNA Vaccine And Drug Development.
-
Does Vaccine Protect Against Omicron? Zhang Wenhong : Vaccination Booster Is Still An Effective Tool To Deal With Omicron
-
Shanghai Company's Self-Developed COVID-19 mRNA Vaccine Approved For Clinical Trials And mRNA Vaccines Animal Trials
-
mRNA Vaccine Production Process : LNP Delivery Technology
Recommend Reading
-
EFSA Reaffirms Safety of E948 Oxygen and E949 Hydrogen in All Foods No Health Risks Detected
-
Novo Nordisk Reports Theft of Six Drug Batches in India Authorities Warn of Severe Patient Safety Risks
-
Indian Pharma Urges US to Exempt Generics as 50 Percent Tariffs Loom National Security Probe Sparks Supply Fears
-
EFSA Confirms Safety of Vitamin E TPGS as Food Additive New Opinion Covers Multiple Use Levels
-
Parliamentary Panel Urges Expanded Price Controls as Dozens of Cancer Drugs Remain Unregulated
-
HNO2 (Nitrous Acid): Properties, Uses, and Safety
-
BASF Technology with CFRP Lands in Nanjing: High-Performance Dispersant Production Line Officially Commissioned
-
Heptane: Properties, Uses, and Industrial Applications
-
DMF Market Prices Remain Stable with Balanced Supply and Demand in China
-
Both Supply and Demand Weak, Plus Prices Falling Below the Moving Average—Isooctanol Prices Fluctuate and Decline in April